60 Degrees Pharmaceuticals Files 8-K
Ticker: SXTPW · Form: 8-K · Filed: Oct 8, 2024 · CIK: 1946563
| Field | Detail |
|---|---|
| Company | 60 Degrees Pharmaceuticals, Inc. (SXTPW) |
| Form Type | 8-K |
| Filed Date | Oct 8, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, regulatory-filing, pharmaceuticals
TL;DR
60 Degrees Pharma filed an 8-K on Oct 2nd. Check for updates.
AI Summary
On October 2, 2024, 60 Degrees Pharmaceuticals, Inc. filed an 8-K report detailing other events and financial statements. The company, incorporated in Delaware, is involved in pharmaceutical preparations.
Why It Matters
This filing indicates an update to the company's regulatory disclosures, which could contain material information for investors.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for 'Other Events' and does not appear to disclose significant negative or positive events.
Key Numbers
- 001-41719 — SEC File Number (Identifies the company's filing with the SEC)
- 45-2406880 — IRS Employer Identification Number (Company's tax identification number)
Key Players & Entities
- 60 DEGREES PHARMACEUTICALS, INC. (company) — Registrant
- October 2, 2024 (date) — Earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- 20036 (zip_code) — Principal executive office zip code
FAQ
What specific 'Other Events' are detailed in this 8-K filing?
The provided text does not specify the 'Other Events' beyond stating that it is an item reported in the 8-K.
What is the principal executive office address of 60 Degrees Pharmaceuticals, Inc.?
The principal executive office is located at 1025 Connecticut Avenue NW, Suite 1000, Washington, D.C. 20036.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on October 2, 2024.
In which state is 60 Degrees Pharmaceuticals, Inc. incorporated?
The company is incorporated in Delaware.
What is the SIC code for 60 Degrees Pharmaceuticals, Inc.?
The Standard Industrial Classification (SIC) code is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 571 words · 2 min read · ~2 pages · Grade level 11.3 · Accepted 2024-10-08 08:17:40
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 SXTP The Nasdaq Stock Market LLC
Filing Documents
- ea0217026-8k_60degrees.htm (8-K) — 32KB
- ea021702601ex99-1_60degrees.htm (EX-99.1) — 25KB
- ex99-1_001.jpg (GRAPHIC) — 4KB
- 0001213900-24-086079.txt ( ) — 286KB
- sxtp-20241002.xsd (EX-101.SCH) — 4KB
- sxtp-20241002_def.xml (EX-101.DEF) — 26KB
- sxtp-20241002_lab.xml (EX-101.LAB) — 36KB
- sxtp-20241002_pre.xml (EX-101.PRE) — 25KB
- ea0217026-8k_60degrees_htm.xml (XML) — 6KB
01. Other Events
Item 8.01. Other Events. On October 3, 2024, 60 Degrees Pharmaceuticals, Inc. (the "Company") issued a press release announcing that the Company had commenced a nine-month promotional pilot to bring greater awareness of ARAKODA (tafenoquine) and its benefits to patients and healthcare providers who prescribe it. The pilot program includes inside, or virtual, sales representatives who will conduct outreach to prospective and current ARAKODA customers to promote the co-pay program and increase sales. The information set forth under this Item 8.01, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
01 Financial
Item 9.01 Financial (d) Exhibits. The following exhibits are being filed herewith: Exhibit No. Description 99.1 Press Release of 60 Degrees Pharmaceuticals, Inc. dated as October 3, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: October 8, 2024 60 DEGREES PHARMACEUTICALS, INC. By: /s/ Geoffrey Dow Name: Geoffrey Dow Title: Chief Executive Officer and President 2